Joseph Buscema

5.2k total citations
52 papers, 822 citations indexed

About

Joseph Buscema is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Joseph Buscema has authored 52 papers receiving a total of 822 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Reproductive Medicine, 17 papers in Oncology and 15 papers in Obstetrics and Gynecology. Recurrent topics in Joseph Buscema's work include Ovarian cancer diagnosis and treatment (26 papers), Endometrial and Cervical Cancer Treatments (13 papers) and Cervical Cancer and HPV Research (10 papers). Joseph Buscema is often cited by papers focused on Ovarian cancer diagnosis and treatment (26 papers), Endometrial and Cervical Cancer Treatments (13 papers) and Cervical Cancer and HPV Research (10 papers). Joseph Buscema collaborates with scholars based in United States, Canada and Italy. Joseph Buscema's co-authors include J. Donald Woodruff, K. V. Shah, Woodruff Jd, Zohreh Naghashfar, Neil B. Rosenshein, Jeffrey L. Stern, Donald C. Foster, J L Stern, John L. Currie and R Daniel and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.

In The Last Decade

Joseph Buscema

49 papers receiving 777 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joseph Buscema United States	18	346	246	239	212	203	52	822
Anisa Kanbour United States	19	217 0.6×	251 1.0×	234 1.0×	219 1.0×	240 1.2×	44	942
T. Küçükali Türkiye	19	315 0.9×	211 0.9×	216 0.9×	87 0.4×	324 1.6×	61	842
Daisy M. D. S. Sie‐Go Netherlands	19	298 0.9×	257 1.0×	227 0.9×	242 1.1×	396 2.0×	33	1.0k
Hilary A. McBride United Kingdom	16	419 1.2×	266 1.1×	279 1.2×	170 0.8×	463 2.3×	19	1.0k
Ciaran O’Neill United Kingdom	9	226 0.7×	141 0.6×	160 0.7×	153 0.7×	203 1.0×	13	598
Shih‐Hung Huang Taiwan	16	200 0.6×	265 1.1×	143 0.6×	127 0.6×	103 0.5×	54	718
Nine van der Vange Netherlands	14	234 0.7×	367 1.5×	343 1.4×	141 0.7×	111 0.5×	23	836
C. Meg McLachlin Canada	19	117 0.3×	348 1.4×	498 2.1×	289 1.4×	143 0.7×	45	989
Michael L. Cibull United States	16	241 0.7×	255 1.0×	116 0.5×	233 1.1×	159 0.8×	34	1.0k

Countries citing papers authored by Joseph Buscema

Since Specialization

Citations

This map shows the geographic impact of Joseph Buscema's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Buscema with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Buscema more than expected).

Fields of papers citing papers by Joseph Buscema

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Buscema. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Buscema. The network helps show where Joseph Buscema may publish in the future.

Co-authorship network of co-authors of Joseph Buscema

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Buscema. A scholar is included among the top collaborators of Joseph Buscema based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Buscema. Joseph Buscema is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cloven, Noelle, Ira Winer, Eric Lee, et al.. (2025). 1121P Rinatabart sesutecan (Rina-S®) for patients with advanced or recurrent endometrial cancer (a/r EC): Update from dose expansion cohort B2 of RAINFOL™-01. Annals of Oncology. 36. S700–S700.

Valabrega, Giorgio, Ignace Vergote, Debra L. Richardson, et al.. (2025). Longer-Term Safety And Efficacy Of Selinexor Maintenance Therapy For Patients With TP53wt Advanced Or Recurrent Endometrial Cancer: Follow-Up Subgroup Analysis Of The ENGOT-EN5/GOG-3055/SIENDO Study. International Journal of Gynecological Cancer. 35(2). 100081–100081. 1 indexed citations

Herzog, Thomas J., John B. Liao, Lyndsay Willmott, et al.. (2025). An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044). Gynecologic Oncology. 194. 145–152. 2 indexed citations

Winer, Ira, Noelle Cloven, Debra L. Richardson, et al.. (2025). Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: First disclosure from dose expansion cohort B2 of the GTC1184-01 study.. Journal of Clinical Oncology. 43(16_suppl). 3039–3039.

O’Malley, David M., Bradley Monk, Myong Cheol Lim, et al.. (2024). Final safety results from ATHENA–MONO (GOG-3020/ENGOT-ov45), a randomized, placebo-controlled, double-blind, phase 3 trial evaluating rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer.. Journal of Clinical Oncology. 42(16_suppl). 5554–5554. 4 indexed citations

Ghamande, Sharad, Lars Hanker, Destin Black, et al.. (2024). Dostarlimab plus chemotherapy followed by dostarlimab plus niraparib maintenance therapy among patients with primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Gynecologic Oncology. 190. S6–S6. 11 indexed citations

Friedman, Claire F., Charles Anderson, John P. Hays, et al.. (2024). EV257/#1106 Upgrade: phase 1 trial of the NaPi2b-directed dolaflexin antibody drug conjugate UpRi in combination with carboplatin in patients with platinum-sensitive ovarian cancer (PSOC). A215.1–A215. 1 indexed citations

Mirza, Mansoor Raza, Sudarshan Sharma, Jørn Herrstedt, et al.. (2023). 740MO Dostarlimab + chemotherapy for the treatment of primary advanced or recurrent endometrial cancer (pA/rEC): Analysis of progression free survival (PFS) and overall survival (OS) outcomes by molecular classification in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial. Annals of Oncology. 34. S507–S507. 20 indexed citations

Mirza, Mansoor Raza, Mark S. Shahin, Matthew A. Powell, et al.. (2023). Patient-reported outcomes (PROs) in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab (D) plus carboplatin/paclitaxel (CP) compared with CP in the ENGOT-EN6/GOG3031/RUBY trial.. JCO Oncology Practice. 19(11_suppl). 332–332. 1 indexed citations

10.

Auranen, Annika, Destin Black, Vladyslav Sukhin, et al.. (2023). #540 Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). A11.2–A12. 2 indexed citations

11.

Werner, Theresa L., Nehal J. Lakhani, William J. Edenfield, et al.. (2022). 32 UPGRADE: phase 1 combination trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer. Gynecologic Oncology Reports. 44. S16–S16. 1 indexed citations

12.

Swisher, Elizabeth M., Austin Miller, Elise C. Kohn, et al.. (2021). LBA34 Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004. Annals of Oncology. 32. S1309–S1309. 4 indexed citations

13.

Hamilton, Erika, Minal Barve, Anthony W. Tolcher, et al.. (2020). 836P Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate. Annals of Oncology. 31. S627–S628. 11 indexed citations

14.

Oza, Amit M., Ursula A. Matulonis, Susanne Malander, et al.. (2018). Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. The Lancet Oncology. 19(8). 1117–1125. 87 indexed citations

15.

Cui, Jing, et al.. (2017). Malignant Female Adnexal Tumor of Probable Wolffian Origin: Case Report and Literature Review. International Journal of Gynecological Pathology. 37(4). 331–337. 11 indexed citations

16.

Oza, Amit M., Ursula A. Matulonis, Susanne Malander, et al.. (2017). Quality of life in patients with recurrent ovarian cancer (OC) treated with niraparib: Results from the ENGOT-OV16/NOVA Trial. Annals of Oncology. 28. v330–v330. 7 indexed citations

17.

Leake, J., Joseph Buscema, Kathleen R. Cho, & John L. Currie. (1991). Dermatofibrosarcoma protuberans of the vulva. Gynecologic Oncology. 41(3). 245–249. 24 indexed citations

18.

McLellan, Robert K., Joseph Buscema, E Guerrero, et al.. (1990). Investigation of ovarian neoplasia of low malignant potential for human papillomavirus. Gynecologic Oncology. 38(3). 383–385. 21 indexed citations

19.

Shah, K. V. & Joseph Buscema. (1988). Genital Warts, Papillomaviruses, and Genital Malignancies. Annual Review of Medicine. 39(1). 371–379. 18 indexed citations

20.

Naghashfar, Zohreh, N. Rosenshein, Attila T. Lörincz, Joseph Buscema, & K. V. Shah. (1987). Characterization of Human Papillomavirus Type 45, a New Type 18-related Virus of the Genital Tract. Journal of General Virology. 68(12). 3073–3079. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact